Literature DB >> 23786997

Analysis of intratumor heterogeneity of EGFR mutations in mixed type lung adenocarcinoma.

Nanae Tomonaga1, Yoichi Nakamura, Hiroyuki Yamaguchi, Takaya Ikeda, Kosuke Mizoguchi, Kohei Motoshima, Seiji Doi, Katsumi Nakatomi, Tetsuya Iida, Tomayoshi Hayashi, Takeshi Nagayasu, Kazuhiro Tsukamoto, Shigeru Kohno.   

Abstract

BACKGROUND: Epidermal growth factor receptor mutations are predictive of the success of EGFR tyrosine kinase inhibitor treatment in patients with advanced non--small-cell lung cancer. As with other solid tumors, lung cancer is thought to be the result of an accumulation of genetic alterations after exposure to carcinogens. The aim of the present study was to clarify the relationship between multistep carcinogenesis and the accumulation of EGFR mutations. PATIENTS AND METHODS: The intratumor heterogeneity of EGFR mutations was analyzed in 38 patients with resected mixed-type lung adenocarcinoma according to histological patterns, and the clinical features of the patients harboring intratumor heterogeneity of EGFR mutations were evaluated.
RESULTS: Intratumor heterogeneity of EGFR mutations was detected in 9 of 38 tumors. EGFR mutations were more common in the bronchioloalveolar (lepidic) carcinoma pattern than in the papillary and acinar patterns, although this difference was not significant. However, there was a significant correlation between intratumor heterogeneity of EGFR mutations and smoking history (P < .043).
CONCLUSION: Intratumor heterogeneity of EGFR mutations correlates with the distribution of histological subtype in mixed type adenocarcinoma and is associated with smoking history.
Copyright © 2013 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  EGFR mutations; Heterogeneity; Mixed type adenocarcinoma; Non–small-cell lung cancer; Smoking

Mesh:

Substances:

Year:  2013        PMID: 23786997     DOI: 10.1016/j.cllc.2013.04.005

Source DB:  PubMed          Journal:  Clin Lung Cancer        ISSN: 1525-7304            Impact factor:   4.785


  12 in total

1.  Radiomic Features Are Associated With EGFR Mutation Status in Lung Adenocarcinomas.

Authors:  Ying Liu; Jongphil Kim; Yoganand Balagurunathan; Qian Li; Alberto L Garcia; Olya Stringfield; Zhaoxiang Ye; Robert J Gillies
Journal:  Clin Lung Cancer       Date:  2016-02-16       Impact factor: 4.785

2.  Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: A case report.

Authors:  Fangwen Zou; Guiyuan Xie; Jin-An Ma; Dong-Ai Zhou; Y I Jiang; Jiao-Yun Zheng
Journal:  Oncol Lett       Date:  2015-03-18       Impact factor: 2.967

3.  Influence of chemotherapy on EGFR mutation status.

Authors:  Yung-Hung Luo; Yuh-Min Chen
Journal:  Transl Lung Cancer Res       Date:  2013-12

4.  EGFR mutation heterogeneity and mixed response to EGFR tyrosine kinase inhibitors of non small cell lung cancer: a clue to overcoming resistance.

Authors:  Jordi Remon; Margarita Majem
Journal:  Transl Lung Cancer Res       Date:  2013-12

5.  Intratumoral Heterogeneity of ALK-Rearranged and ALK/EGFR Coaltered Lung Adenocarcinoma.

Authors:  Weijing Cai; Dongmei Lin; Chunyan Wu; Xuefei Li; Chao Zhao; Limou Zheng; Shannon Chuai; Ke Fei; Caicun Zhou; Fred R Hirsch
Journal:  J Clin Oncol       Date:  2015-09-28       Impact factor: 44.544

6.  Immune evolution from preneoplasia to invasive lung adenocarcinomas and underlying molecular features.

Authors:  Hitoshi Dejima; Xin Hu; Runzhe Chen; Jiexin Zhang; Junya Fujimoto; Edwin R Parra; Cara Haymaker; Shawna M Hubert; Dzifa Duose; Luisa M Solis; Dan Su; Junya Fukuoka; Kazuhiro Tabata; Hoa H N Pham; Nicholas Mcgranahan; Baili Zhang; Jie Ye; Lisha Ying; Latasha Little; Curtis Gumbs; Chi-Wan Chow; Marcos Roberto Estecio; Myrna C B Godoy; Mara B Antonoff; Boris Sepesi; Harvey I Pass; Carmen Behrens; Jianhua Zhang; Ara A Vaporciyan; John V Heymach; Paul Scheet; J Jack Lee; Jia Wu; P Andrew Futreal; Alexandre Reuben; Humam Kadara; Ignacio I Wistuba; Jianjun Zhang
Journal:  Nat Commun       Date:  2021-05-11       Impact factor: 14.919

7.  Intratumor Heterogeneity of ALK-Rearrangements and Homogeneity of EGFR-Mutations in Mixed Lung Adenocarcinoma.

Authors:  Federica Zito Marino; Federica Zito Marino; Giuseppina Liguori; Gabriella Aquino; Elvira La Mantia; Silvano Bosari; Stefano Ferrero; Lorenzo Rosso; Gabriella Gaudioso; Nicla De Rosa; Marianna Scrima; Nicola Martucci; Antonello La Rocca; Nicola Normanno; Alessandro Morabito; Gaetano Rocco; Gerardo Botti; Renato Franco
Journal:  PLoS One       Date:  2015-09-30       Impact factor: 3.240

8.  Clinically significant sub-clonality for common drivers can be detected in 26% of KRAS/EGFR mutated lung adenocarcinomas.

Authors:  Einav Simon; Tova Bick; Shada Sarji; Talia Shentzer; Elad Prinz; Liza Yehiam; Edmond Sabo; Ofer Ben-Izhak; Dov Hershkovitz
Journal:  Oncotarget       Date:  2017-07-11

9.  MicroRNA Expression Profile on Solid Subtype of Invasive Lung Adenocarcinoma Reveals a Panel of Four miRNAs to Be Associated with Poor Prognosis in Chinese Patients.

Authors:  Yong-Qiang Zhang; Wei-Ya Wang; Jian-Xin Xue; Yan Xu; Ping Fan; Bennett Adam Caughey; Wei-Wei Tan; Gui-Qun Cao; Li-Li Jiang; You Lu; Kang Zhang; Xun Hu
Journal:  J Cancer       Date:  2016-07-18       Impact factor: 4.207

10.  Assessing the Clinical Utility of Computed Tomography-Based Radiomics.

Authors:  Julia Lai-Kwon; Shankar Siva; Jeremy Lewin
Journal:  Oncologist       Date:  2018-05-04
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.